Latest Sulfoxides Stories
In an evaluation of contemporary antireflux therapies for chronic gastroesophageal reflux disease (GERD), most patients who received treatment with either the proton pump inhibitor esomeprazole or laparoscopic antireflux surgery achieved and remained in disease remission for 5 years.
FRAZER, Pa., May 6, 2011 /PRNewswire/ -- At the Society of General Internal Medicine's 34th Annual Meeting in Phoenix, Ariz. today, Cephalon, Inc. (Nasdaq: CEPH) presented positive results from a phase IV trial of nearly 400 people with excessive sleepiness associated with shift work disorder.
FRAZER, Pa., April 21, 2011 /PRNewswire/ -- Cephalon, Inc.
HOUSTON, April 19, 2011 /PRNewswire/ -- An Ohio woman suffered bone deterioration and broken bones because of hidden risks with pharmaceutical giant AstraZeneca's acid reflux drug Nexium, The Gibson Law Firm alleges in a lawsuit filed today in Texas federal court. Filed in the U.S.
MISSISSAUGA, Ontario, April 11, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today filed with the Securities and Exchange Commission a presentation in connection with its written consent solicitation to stockholders of Cephalon, Inc.
NEW ORLEANS, April 5, 2011 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. (Takeda) announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate).
CHAPEL HILL, N.C., Feb. 14, 2011 /PRNewswire/ -- Thought Leader Select, a Research Triangle, NC firm focused on collaborations between the biopharmaceutical industry and the medical community, announces the launch of a new media partnership with biopharmaceutical industry blog Marketing4Health.
FRAZER, Pa., Jan. 25, 2011 /PRNewswire/ -- Cephalon, Inc.
RADNOR, Pa., Jan. 19, 2011 /PRNewswire/ -- HTH Worldwide, a global health and safety services company, today announced the expansion of its mobile and online brand name medication translation guide for world travelers.
FRAZER, Pa., Dec. 27, 2010 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the company received a second Complete Response Letter from the U.S.
- An armed gangster.